David A Hafler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9414368/publications.pdf

Version: 2024-02-01

93 papers	16,156 citations	44069 48 h-index	40979 93 g-index
100 all docs	100 docs citations	100 times ranked	23643 citing authors

#	Article	IF	Citations
1	Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature, 2015, 518, 337-343.	27.8	1,669
2	CD4+CD25high Regulatory Cells in Human Peripheral Blood. Journal of Immunology, 2001, 167, 1245-1253.	0.8	1,655
3	Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study. New England Journal of Medicine, 2007, 357, 851-862.	27.0	1,529
4	T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis. Nature, 1990, 346, 183-187.	27.8	866
5	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, .	12.6	710
6	Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses. Immunity, 2014, 40, 569-581.	14.3	702
7	Extreme Th1 bias of invariant VÎ±24JÎ±Q T cells in type 1 diabetes. Nature, 1998, 391, 177-181.	27.8	639
8	Pervasive Sharing of Genetic Effects in Autoimmune Disease. PLoS Genetics, 2011, 7, e1002254.	3.5	540
9	Regulatory T cells in autoimmune disease. Nature Immunology, 2018, 19, 665-673.	14.5	488
10	Identification of T helper type 1â€“like, Foxp3+ regulatory T cells in human autoimmune disease. Nature Medicine, 2011, 17, 673-675.	30.7	420
11	pRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires. Bioinformatics, 2014, 30, 1930-1932.	4.1	417
12	B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Science Translational Medicine, 2014, 6, 248ra107.	12.4	394
13	In Vivo Activated T Lymphocytes in the Peripheral Blood and Cerebrospinal Fluid of Patients with Multiple Sclerosis. New England Journal of Medicine, 1985, 312, 1405-1411.	27.0	310
14	Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nature Reviews Neurology, 2015, 11, 504-514.	10.1	307
15	Multiple sclerosisâ€”a quiet revolution. Nature Reviews Neurology, 2015, 11, 134-142.	10.1	286
16	From Big Data to Precision Medicine. Frontiers in Medicine, 2019, 6, 34.	2.6	273
17	Small-Molecule RORÎ³t Antagonists Inhibit T Helper 17 Cell Transcriptional Network by Divergent Mechanisms. Immunity, 2014, 40, 477-489.	14.3	253
18	Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Science Translational Medicine, 2015, 7, 287ra74.	12.4	246

#	Article	IF	Citations
19	Models of Somatic Hypermutation Targeting and Substitution Based on Synonymous Mutations from High-Throughput Immunoglobulin Sequencing Data. Frontiers in Immunology, 2013, 4, 358.	4.8	197
20	Polyspecificity of T cell and B cell receptor recognition. Seminars in Immunology, 2007, 19, 216-224.	5.6	194
21	Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain, 2011, 134, 534-541.	7.6	186
22	Enhanced suppressor function of TIMâ€3⁺FoxP3⁺ regulatory TÂcells. European Journal of Immunology, 2014, 44, 2703-2711.	2.9	182
23	PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight, 2016, 1, .	5.0	182
24	Dissection of artifactual and confounding glial signatures by single-cell sequencing of mouse and human brain. Nature Neuroscience, 2022, 25, 306-316.	14.8	166
25	Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity, 2021, 54, 1083-1095.e7.	14.3	164
26	The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. Journal of Clinical Immunology, 2001, 21, 81-92.	3.8	155
27	Immunologic Mechanisms and Therapy in Multiple Sclerosis. Immunological Reviews, 1995, 144, 75-107.	6.0	142
28	Biomarkers in multiple sclerosis. Clinical Immunology, 2015, 161, 51-58.	3.2	139
29	Lack of TIM-3 Immunoregulation in Multiple Sclerosis. Journal of Immunology, 2008, 180, 4409-4414.	0.8	121
30	Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Nature Communications, 2022, 13, 440.	12.8	100
31	TLR7 induces anergy in human CD4+ T cells. Nature Immunology, 2015, 16, 118-128.	14.5	94
32	Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia. Annals of Neurology, 1997, 42, 313-318.	5.3	92
33	In vivo labeling of blood T cells: Rapid traffic into cerebrospinal fluid in multiple sclerosis. Annals of Neurology, 1987, 22, 89-93.	5.3	90
34	Activated Î²-catenin in Foxp3+ regulatory T cells links inflammatory environments to autoimmunity. Nature Immunology, 2018, 19, 1391-1402.	14.5	90
35	<scp>AKT</scp> isoforms modulate Th1â€like Treg generation and function in human autoimmune disease. EMBO Reports, 2016, 17, 1169-1183.	4.5	88
36	Single-cell RNA sequencing reveals microglia-like cells in cerebrospinal fluid during virologically suppressed HIV. JCI Insight, 2018, 3, .	5.0	85

#	Article	IF	Citations
37	TIGIT signaling restores suppressor function of Th1 Tregs. JCI Insight, 2019, 4, .	5.0	82
38	Genetic variants associated with autoimmunity drive NFÎºB signaling and responses to inflammatory stimuli. Science Translational Medicine, 2015, 7, 291ra93.	12.4	81
39	Loss of functional suppression is linked to decreases in circulating suppressor inducer (CD4 + 2H4 +) T Cells in multiple sclerosis. Annals of Neurology, 1988, 24, 185-191.	5.3	79
40	Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the lewis rat and strain 13 guinea pig. Annals of Neurology, 1991, 29, 615-622.	5.3	74
41	Transcriptomic and clonal characterization of T cells in the human central nervous system. Science Immunology, 2020, 5, .	11.9	73
42	Common Tâ€cell receptor V Î² usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. Annals of Neurology, 1991, 29, 33-40.	5.3	68
43	CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology, 2016, 86, 1553-1556.	1.1	65
44	Decrease of suppressor inducer (cd4+ 2h4+) t cells in multiple sclerosis cerebrospinal fluid. Annals of Neurology, 1989, 25, 494-499.	5.3	63
45	TIMs: central regulators of immune responses. Journal of Experimental Medicine, 2008, 205, 2699-2701.	8.5	57
46	Oleic acid restores suppressive defects in tissue-resident FOXP3 Tregs from patients with multiple sclerosis. Journal of Clinical Investigation, 2021, 131, .	8.2	56
47	Enhanced astrocyte responses are driven by a genetic risk allele associated with multiple sclerosis. Nature Communications, 2018, 9, 5337.	12.8	54
48	Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nature Immunology, 2022, 23, 632-642.	14.5	54
49	Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.. Journal of Clinical Oncology, 2015, 33, 3010-3010.	1.6	52
50	Production of Proinflammatory Cytokines by Monocytes in Liver-Transplanted Recipients with De Novo Autoimmune Hepatitis Is Enhanced and Induces TH1-like Regulatory T Cells. Journal of Immunology, 2016, 196, 4040-4051.	0.8	51
51	Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology, 2022, 98, .	1.1	51
52	Multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 723-730.	1.8	50
53	NEBULA is a fast negative binomial mixed model for differential or co-expression analysis of large-scale multi-subject single-cell data. Communications Biology, 2021, 4, 629.	4.4	50
54	Regulatory T Cells: From Discovery to Autoimmunity. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a029041.	6.2	49

#	Article	IF	Citations
55	National Heart, Lung, and Blood Institute Working Group Report on Salt in Human Health and Sickness. Hypertension, 2016, 68, 281-288.	2.7	48
56	Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. Journal of Experimental Medicine, 2021, 218, .	8.5	48
57	Solving Immunology?. Trends in Immunology, 2017, 38, 116-127.	6.8	45
58	Autoimmunity following viral infection: demonstration of monoclonal antibodies against normal tissue following infection of mice with reovirus and demonstration of shared antigenicity between virus and lymphocytes. European Journal of Immunology, 1984, 14, 561-565.	2.9	43
59	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology, 2017, 8, 1844.	4.8	43
60	Aedes aegypti AgBR1 antibodies modulate early Zika virus infection of mice. Nature Microbiology, 2019, 4, 948-955.	13.3	43
61	Joint Modeling and Registration of Cell Populations in Cohorts of High-Dimensional Flow Cytometric Data. PLoS ONE, 2014, 9, e100334.	2.5	41
62	Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo. Journal of Autoimmunity, 2019, 96, 40-49.	6.5	39
63	Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived Immunoglobulins. Frontiers in Immunology, 2015, 6, 600.	4.8	37
64	Monoallelic expression of the human <i>FOXP2</i> speech gene. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6848-6854.	7.1	36
65	Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294.	4.2	36
66	Systems Immunology Reveals Markers of Susceptibility to West Nile Virus Infection. Vaccine Journal, 2015, 22, 6-16.	3.1	35
67	Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme. PLoS ONE, 2017, 12, e0181538.	2.5	34
68	CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome. Journal of Translational Autoimmunity, 2020, 3, 100032.	4.0	32
69	Cutting Edge: Distinct B Cell Repertoires Characterize Patients with Mild and Severe COVID-19. Journal of Immunology, 2021, 206, 2785-2790.	0.8	31
70	Podoplanin is a negative regulator of Th17 inflammation. JCI Insight, 2017, 2, .	5.0	29
71	Applying a new generation of genetic maps to understand human inflammatory disease. Nature Reviews Immunology, 2005, 5, 83-91.	22.7	23
72	Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity. Journal of Immunology, 2019, 202, 2210-2219.	0.8	22

#	Article	IF	Citations
73	Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	22
74	The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Science Immunology, 2021, 6, eabf4034.	11.9	22
75	TCR-sequencing in cancer and autoimmunity: barcodes and beyond. Trends in Immunology, 2022, 43, 180-194.	6.8	20
76	Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. EBioMedicine, 2019, 42, 76-85.	6.1	18
77	Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. New England Journal of Medicine, 2016, 374, 1495-1496.	27.0	17
78	The Human Functional Genomics Project: Understanding Generation of Diversity. Cell, 2016, 167, 894-896.	28.9	16
79	Cytokines and interventional immunology. Nature Reviews Immunology, 2007, 7, 423-423.	22.7	13
80	Coâ€inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunological Reviews, 2017, 276, 9-25.	6.0	13
81	Basic principles of neuroimmunology. Seminars in Immunopathology, 2022, 44, 685-695.	6.1	10
82	Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells. Cancers, 2021, 13, 1049.	3.7	9
83	Sodium-activated macrophages: the salt mine expands. Cell Research, 2015, 25, 885-886.	12.0	6
84	Population genetics meets single-cell sequencing. Science, 2022, 376, 134-135.	12.6	5
85	Linking Genotype to Clinical Phenotype in Multiple Sclerosis. JAMA Neurology, 2016, 73, 777.	9.0	4
86	A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).. Journal of Clinical Oncology, 2021, 39, TPS2676-TPS2676.	1.6	4
87	Cumulative Experience with High-Dose Intravenous Cyclophosphamide and ACTH Therapy in Chronic Progressive Multiple Sclerosis. Annals of the New York Academy of Sciences, 1988, 540, 535-536.	3.8	3
88	Immunohistochemical Analysis of Suppressor-Inducer and Helper-Inducer T Cells in Multiple Sclerosis Brain Tissue. Annals of the New York Academy of Sciences, 1988, 540, 306-308.	3.8	2
89	A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).. Journal of Clinical Oncology, 2020, 38, TPS3158-TPS3158.	1.6	2
90	Editorial: T Cell Regulation by the Environment. Frontiers in Immunology, 2015, 6, 229.	4.8	1

#	Article	IF	Citations
91	Thymic Selection: To Thine Own Self Be True. Immunity, 2015, 42, 788-789.	14.3	1
92	Epigenetic fine-mapping: identification of causal mechanisms for autoimmunity. Current Opinion in Immunology, 2020, 67, 50-56.	5.5	1
93	23Na imaging: Worth its salt for understanding multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2110799118.	7.1	0